It is frequently deregulated in a majority of human cancers through receptor tyrosine kinase activation or amplification such as loss of PTEN (phosphatase and tensin homolog), activating mutations of PIK3CA, or other downstream effectors of PI3K/Akt signaling. This evidence concerns the gene PTEN and cancer.